Its shares are up 134% year-to-date. The stock soared in late February after the FDA backed its weight loss drug Qnexa. Arena also develops drugs for cardiovascular, central nervous system, inflammatory and metabolic diseases. Up 71% …
If you want a Stock Review on GRFS, HALO, ILMN, or VVUS then come over to http://dailystocktracker.com/register/ …
I know very little about cheap stocks, so I called my old pal Huckleberry Ginsberg, CSA (cheap stock analyst). The following are Huck's recommendations: Vivus (VVUS-$1.19), founded in 1991, is a $125 million-revenue …
Goerie3mon
If you want a Stock Review on GRFS, HALO, ILMN, or VVUS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Thursday, benchmark US indices were in bullish colors as the …
4 KMOV1mon
Drugmaker Vivus (NASDAQ:VVUS) said Tuesday that U.S. regulators have delayed a ... The extension is standard to provide time for a full review, Vivus said. Vivus stock declined 4 percent premarket to $22.05. Qnexa raised patients’ …
these are the four most volatile stocks with significant volume, providing ample intra-day opportunity for traders. BlackBerry (Nasdaq:BBRY) is prone to having some large intra-day moves. Based on the criterion, this is the most …
VIVUS Inc. VVUS reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period. Earnings beat the Zacks Consensus Estimate of a loss of 9 cents by 700%. Shares of the biotech …
Yahoo!7mon
Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
VIVUS, Inc. (NASDAQ:VVUS) shares soared 11% to $20.58 after Bloomberg Industries claims the prescription insurer …